Atossa Therapeutics, Inc. (FRA:YAG)

Market Cap	18.30M -78.8%
Revenue (ttm)	n/a
Net Income	-32.65M
EPS	-3.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.280
Previous Close	3.860
Day's Range	2.280 - 2.280
52-Week Range	2.280 - 16.230
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Atossa Therapeutics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YAG

Financial Performance

Financial numbers in USD